125 related articles for article (PubMed ID: 12077331)
1. The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes.
Mudhasani R; Fontes JD
Mol Cell Biol; 2002 Jul; 22(14):5019-26. PubMed ID: 12077331
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.
Bhat KP; Truax AD; Greer SF
J Biol Chem; 2010 Aug; 285(34):25893-903. PubMed ID: 20538595
[TBL] [Abstract][Full Text] [Related]
3. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator.
Douhan J; Lieberson R; Knoll JH; Zhou H; Glimcher LH
J Exp Med; 1997 Jun; 185(11):1885-95. PubMed ID: 9166418
[TBL] [Abstract][Full Text] [Related]
4. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator.
Kretsovali A; Agalioti T; Spilianakis C; Tzortzakaki E; Merika M; Papamatheakis J
Mol Cell Biol; 1998 Nov; 18(11):6777-83. PubMed ID: 9774691
[TBL] [Abstract][Full Text] [Related]
5. The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.
León Machado JA; Steimle V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499042
[TBL] [Abstract][Full Text] [Related]
6. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes.
Fontes JD; Kanazawa S; Jean D; Peterlin BM
Mol Cell Biol; 1999 Jan; 19(1):941-7. PubMed ID: 9858618
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma-induced chromatin remodeling at the CIITA locus is BRG1 dependent.
Pattenden SG; Klose R; Karaskov E; Bremner R
EMBO J; 2002 Apr; 21(8):1978-86. PubMed ID: 11953317
[TBL] [Abstract][Full Text] [Related]
8. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants.
Chin KC; Li GG; Ting JP
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2501-6. PubMed ID: 9122224
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide CIITA-binding profile identifies sequence preferences that dictate function versus recruitment.
Scharer CD; Choi NM; Barwick BG; Majumder P; Lohsen S; Boss JM
Nucleic Acids Res; 2015 Mar; 43(6):3128-42. PubMed ID: 25753668
[TBL] [Abstract][Full Text] [Related]
10. The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation.
Barker N; Hurlstone A; Musisi H; Miles A; Bienz M; Clevers H
EMBO J; 2001 Sep; 20(17):4935-43. PubMed ID: 11532957
[TBL] [Abstract][Full Text] [Related]
11. Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.
Peretti M; Villard J; Barras E; Zufferey M; Reith W
Mol Cell Biol; 2001 Sep; 21(17):5699-709. PubMed ID: 11486010
[TBL] [Abstract][Full Text] [Related]
12. CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II.
Spilianakis C; Kretsovali A; Agalioti T; Makatounakis T; Thanos D; Papamatheakis J
EMBO J; 2003 Oct; 22(19):5125-36. PubMed ID: 14517250
[TBL] [Abstract][Full Text] [Related]
13. CIITA is not associated with risk of developing rheumatoid arthritis.
Bronson PG; Ramsay PP; Seldin MF; Gregersen PK; Criswell LA; Barcellos LF
Genes Immun; 2011 Apr; 12(3):235-8. PubMed ID: 21248776
[TBL] [Abstract][Full Text] [Related]
14. Abdominal surgery induces long-lasting changes in expression and binding of CTCF with impact on Major Histocompatibility Complex II transcription in circulating human monocytes.
Siegler BH; Thon JN; Altvater M; Schenz J; Larmann J; Weigand MA; Weiterer S
PLoS One; 2023; 18(10):e0293347. PubMed ID: 37878653
[TBL] [Abstract][Full Text] [Related]
15. The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.
Forlani G; Shallak M; Gatta A; Shaik AKB; Accolla RS
Biomed J; 2023 Oct; 46(5):100631. PubMed ID: 37467968
[TBL] [Abstract][Full Text] [Related]
16. BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II.
Redelman-Sidi G; Binyamin A; Antonelli AC; Catalano W; Bean J; Al-Ahmadie H; Jungbluth AA; Glickman MS
Cancer Immunol Res; 2022 Oct; 10(10):1241-1253. PubMed ID: 36040405
[TBL] [Abstract][Full Text] [Related]
17. Identification of small molecule modulators of class II transactivator-I using computational approaches.
Nagasubramanian K; Jha S; Rathore AS; Gupta K
J Biomol Struct Dyn; 2023; 41(17):8349-8361. PubMed ID: 36224172
[TBL] [Abstract][Full Text] [Related]
18. Class II transactivator: mastering the art of major histocompatibility complex expression.
Harton JA; Ting JP
Mol Cell Biol; 2000 Sep; 20(17):6185-94. PubMed ID: 10938095
[No Abstract] [Full Text] [Related]
19. Novel variants in CIITA caused type II bare lymphocyte syndrome: A case report.
Zhang Y; Yokoyama Y; Qing Y; Han C; Zhu J; Yu T; Yin L; Yao R; Wang J
Asian Pac J Allergy Immunol; 2024 Mar; 42(1):81-85. PubMed ID: 33386785
[TBL] [Abstract][Full Text] [Related]
20. Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma.
Tan AK; Henry A; Goffart N; van Logtestijn S; Bours V; Hol EM; Robe PA
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
